Inside PIC/S: Implementing Quality Risk Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside PIC/S: Implementing Quality Risk Management
Representatives to the PIC/S provide an example of methodology for implementing ICH Q9.


Pharmaceutical Technology
Volume 33, Issue 12

The International Conference on Harmonization guideline on quality risk management, ICH Q9, addresses active substances and medicinal products, and was adopted by the European Union and Pharmaceutical Inspection Cooperation Scheme (PIC/S) in Annex 20 of their good manufacturing practice (GMP) guides. Drug manufacturers are gradually implementing quality risk-management principles as introduced in sections 1.5 and 1.6 of the European Union's GMP Guide, Part I. However, the practical methods for these new requirements are still perceived as difficult to interpret and apply.

In this context, a small, informal PIC/S working group is developing an objective and pragmatic example of methodology for ICH Q9 that can be used by the widest audience. The methodology will meet the demands of operators and inspectors and comply with all regulatory requirements. The main axes of this methodology are presented in this article; a complete description with examples of how the methodology can be implemented is available on the PIC/S website ( http://www.picscheme.org/).

The methodology example is meant to be used for training and will not be issued as a PIC/S recommendation or guideline. The example will not influence the outcome of PIC/S inspections.

Primary methodological axes

The proposed methodology comprises an exhaustive review of the various stages that have an effect on the intrinsic quality of the product. These steps include:

  • The inventory and evaluation of primary risks
  • The application of measures for the reduction of these risks
  • The evaluation of residual risks.

For each recorded stage, risk is traditionally assessed according to potential severity and frequency of the risk occuring. The manufacturer's ability to detect risk and the experience gained in performing the step in question also help determine the risk involved.

Integrating a quantified experience factor in risk calculation with an objective scale serves as a major achievement in the field of risk management. Calculated in this manner, the level of evaluated risk expresses the degree of technical mastery acquired in the performance of each process step for the concerned perimeter, without having to take into account the specific characteristics of the products involved. This is the first phase of the methodology and has been named System Risk.

The second phase of the risk-management methodology considers the integration of the particular properties of the products themselves whose System Risk will have been previously assessed. This integration is done using a modulating factor, the P-factor, which, multiplied with the System Risk gives the Total Risk.

The P-factor takes into consideration the intrinsic physicochemical and pharmaco-toxological characteristics of the product as well as parameters expressing knowledge levels and experience gained by the manufacturer for the product concerned.

This dual approach makes it possible to significantly reduce the burden (i.e., resources) of risk management. For example, the methodology avoids the needless repetitions of risk-evaluation steps that are typically conducted during the introduction of a new product.

By implementing a risk-management policy that integrates the steps defined above, a manufacturer in the pharmaceutical area can maintain the relevance of its risk levels and evaluate them for a total risk calculation. A risk-management policy should also envisage provisions for the identification and inclusion of developments that could potentially modify the result of an initial risk evaluation. Such developments may be internal or external to the company and may or may not be integrated into the manufacturer's quality system.

Traditionally, these developments include the management of corrective actions and preventive actions, deviations, change control, and internal and external information (e.g., GMP modification). Finally, a company's methodology of risk management should be organized according to an iterative process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here